Bimanual Motor Skill Learning Through Robotics in Chronic Cerebellar Stroke Survivors and Healthy Individuals

December 10, 2024 updated by: Pr Yves Vandermeeren, MD, PhD, University Hospital of Mont-Godinne
To test capacity of chronic cerebellar stroke patients and healthy individuals to learn and retain a complex bimanual motor skill, trained on the neurorehabilitation robot REAplan® (bimanual version).

Study Overview

Detailed Description

Over 3 consecutive days, healthy individuals and chronic cerebellar stroke patients (1) will be evaluated and (2) will train on the neurorehabilitation robot REAplan®.

They will practice several tasks on the robot REAplan® (bimanual version), requiring either movements with the affected arm (unimanual tasks) or complex, coordinated movements with both arms (bimanual tasks).

In addition, several "classical" clinical scales and tests will be used to evaluate overall motor-sensory-cognitive functions (clinical tests, questionnaires, ...).

Hand/digits motor function will be also evaluated with the kinetic device DexTrain®.

Study Type

Interventional

Enrollment (Estimated)

50

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Namur
      • Yvoir, Namur, Belgium, 5530
        • CHU UCL Namur, Mont-Godinne, Neurology Department, Stroke Unit

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

STROKE PATIENTS:

Inclusion Criteria:

  • having a chronic cerebellar stroke (>6 months)
  • aged 18-90 years
  • with a demonstrated stroke (ischemic or hemorrhagic) lesion on brain imaging

Exclusion Criteria:

  • difficulty in understanding or executing commands
  • drug/alcohol abuse
  • severe aphasia / cognitive deficits interfering with study
  • inability to voluntarily move the affected arm (i.e. complete paralysis of the arm)
  • multiple strokes / dementia / psychiatric condition

HEALTHY INDIVIDUALS:

Inclusion Criteria:

  • 18-90 years

Exclusion Criteria:

  • neurological conditions interfering with the study
  • drug/alcohol abuse
  • pyschiatric condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Chronic Cerebellar Stroke
Participants with a chronic cerebellar stroke
REAplan® rehabilitation robot: training to perform complex, coordinated, bimanual movements
Active Comparator: Healthy Individuals (Controls)
healthy participants
REAplan® rehabilitation robot: training to perform complex, coordinated, bimanual movements

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in bi-SAT
Time Frame: Change between day 1 to 3
Bimanual Speed/Accuracy Trade-off measured by the REAplan robot bimanual Speed/Accuracy Trade-off: mathematical computation of the relationship bewteen speed and accuracy
Change between day 1 to 3
Change in bi-CO
Time Frame: Change between day 1 to 3
Bimanual Coordination factor measured by the REAplan robot bimanual Coordination factor : mathematical measure of the phase coherence between velocities of both arms
Change between day 1 to 3

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
bi-SAT
Time Frame: Day 1 + day 3
On bimanual REACHING (REAplan robot) bimanual Speed/Accurady Trade-off: mathematical computation of the relationship
Day 1 + day 3
bi-CO
Time Frame: Day 1 + day 3
On bimanual REACHING (REAplan robot) bimanual Coordination factor: mathematical measure of the phase coherence between velocities of both arms
Day 1 + day 3
change in bi-Force
Time Frame: Change between day 1 to 3
Bimanual forces : forces exerted in the wrong direction by each arm (Newtons)
Change between day 1 to 3
bi-Force
Time Frame: Day 1 + day 3

On bimanual REACHING (REAplan robot)

bimanual forces : forces exerted in the wrong direction by each arm (Newtons)

Day 1 + day 3
bi-smoothness
Time Frame: Day 1+ day 3
On bimanual REACHING (REAplan robot) Smoothness of movement : Spectral Arc Length (SPARC)
Day 1+ day 3
bi-error
Time Frame: Day 1 + day 3
on bimanual REACHING (REAplan robot) Error in centimeters or degrees during bimanual reaching
Day 1 + day 3
Dextrain
Time Frame: Day 1 + day 3
Kinetic device measuring the movements of each finger: error and co-activation (percentage)
Day 1 + day 3
Dextrain
Time Frame: Day 1 + day 3
Kinetic device measuring the movements of each finger: speed (milliseconds)
Day 1 + day 3
Dextrain
Time Frame: Day 1 + day 3
Kinetic device measuring the movements of each finger: force (Newton)
Day 1 + day 3
BBT
Time Frame: Day 1 + day 3
Box & Blocks Test (timed transfert of blocks from one space to the other)
Day 1 + day 3
Modified International Cooperative Ataxia Rating Scale (MICARS)
Time Frame: Day 1
Ataxia scale A high score describes strong ataxia and a low score describes weak ataxia
Day 1
Fugl Meyer Upper extremity test
Time Frame: Day 2
Tests impairments of the upper limb after stroke
Day 2
Corsi block
Time Frame: Day 2
Tests the visuo-spatial memory
Day 2
Montreal Cognitive Assessment (MoCA)
Time Frame: Day 2
Tests the short-term memory, visuospatial skills, executive functions, attention, concentration, working memory, language and orientation in time and space
Day 2
Abilhand and activlim
Time Frame: Day 3
Questionnaire about the bimanual hability during activities of the daily life
Day 3

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yves Vandermeeren, MD, PhD, University Hospital of Mont-Godinne

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 29, 2021

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

November 2, 2020

First Submitted That Met QC Criteria

November 18, 2020

First Posted (Actual)

November 24, 2020

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

December 10, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

the precise IPD plan has to be worked out in order to find the best public repository

IPD Sharing Time Frame

Up to 2 years after publication of the scientific articles

IPD Sharing Access Criteria

none (public)

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe